Barclays Lowers RadNet (RDNT) Price Target, Says Imaging Business Continues to Outperform

RadNet, Inc. (NASDAQ: RDNT ) is included among the Billionaire George Soros Stock Portfolio: 10 Best Stocks to Buy .

On May 20, Barclays analyst Andrew Mok lowered his price recommendation on RadNet, Inc. (NASDAQ:RDNT) to $65 from $70. It reiterated an Overweight rating on the stock. The analyst said RadNet continues to outperform Lumexa in advanced volume growth and pricing across its imaging business.

In April, RadNet announced a joint venture with Saint Alphonsus Health System through the acquisition of a majority equity stake in Intermountain Medical Imaging, LLC. The company owns five outpatient multi-modality imaging centers in Boise, Idaho.

As part of the partnership, Gem State Radiology will provide radiology interpretation and reporting services to Saint Alphonsus Health System using DeepHealth’s solutions.

RadNet, Inc. (NASDAQ:RDNT) is a national provider of fixed-site diagnostic imaging services in the United States. The company operates a network of 407 owned and/or managed outpatient imaging centers across the country.

While we acknowledge the potential of RDNT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: 10 Best Reddit Stocks to Buy According to Billionaires and 10 Safe Stocks to Buy for the Long Term in 2026